360 ONE Asset Invests in OneSource, Strengthens India’s Speciality Pharma Landscape

The investment comes as OneSource positions itself as a significant player in biologics, drug-device combinations, complex injectables, and soft gelatin capsules.

360 ONE Asset, one of India’s leading asset management firms, has acquired a stake in OneSource Specialty Pharma, a prominent contract development and manufacturing organization (CDMO). 

The investment comes as OneSource positions itself as a significant player in biologics, drug-device combinations, complex injectables, and soft gelatin capsules.

The deal marks a key milestone in OneSource’s growth. The company, recognized for its expertise in manufacturing complex products such as GLP-1 drugs and novel biologics, is among the few Indian firms excelling in niche pharma capabilities. 

With a portfolio that addresses rising global demand, OneSource has built a solid client base, including several renowned pharmaceutical and biotech companies.

OneSource operates five highly automated manufacturing plants, including four US FDA-approved facilities with a strong compliance record. It employs over 1,200 professionals, including 100 scientists and techno-commercial experts, positioning the company to leverage advanced manufacturing technologies and expand its global reach.

Tarun Sharma, Fund Manager (Healthcare and Consumer) at 360 ONE Asset, emphasized the strategic importance of the partnership, stating, “We are backing OneSource, which has built a wide portfolio of capabilities. The company’s leadership in large molecules, complex injectables, and drug-device combinations positions it for the next phase of growth. We look forward to collaborating with OneSource as they continue their innovation and global expansion journey.”

Strengthening Leadership in Biologics

OneSource’s expertise in niche and complex dosage forms remains a key strength. Its focus on biologics, drug-device combinations, and large molecules aligns with global healthcare trends, where demand for precision-driven and high-quality pharmaceutical solutions is growing.

Neeraj Sharma, CEO of OneSource Specialty Pharma, highlighted the company’s robust compliance and integrated solutions. He stated, “Our expertise in niche and complex dosage forms, along with our track record of superior compliance, allows us to provide an integrated, one-stop solution to our global clients. We are glad to welcome 360 ONE Asset as an investor who aligns with our mission to scale further.”